The Centers for Medicare & Medicaid Services Feb. 20 issued a rule proposing changes to the Comprehensive Care for Joint Replacement model, which bundles payment to acute care hospitals for hip and knee replacement surgery. Under this model, hospitals in which a joint replacement has taken place are held financially accountable for episode quality and costs. 

Among other proposals, CMS would extend the CJR model for an additional three years, through Dec. 31, 2023, beyond its current five-year timeline. However, this extension would apply only to hospitals in the 34 metropolitan statistical areas in which participation was mandatory. Hospitals participating in the 33 “voluntary” MSAs, as well as all low-volume and rural hospitals that have elected to participate, will continue to see the model end on Dec. 31, 2020.

The AHA has long been supportive of voluntary participation in alternative payment models as a pathway to potentially improve care coordination and efficiency. As such, the association is disappointed that CMS is not proposing to extend voluntary participation options in the CJR model.
 

Related News Articles

Headline
Applications for the Rural Health Transformation Program are due Nov. 5 to the Centers for Medicare & Medicaid Services. The program will fund $50 billion…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
States have until Sept. 30 to submit an optional letter of intent to the Centers for Medicare & Medicaid Services indicating they plan to apply to the…
Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…